Supplementary Components5737159. antibody continues to be examined in preclinical tumor versions [17, 18]. We also reported previously how the antitumor activity of enavatuzumab has been attributed to three distinct mechanisms of action: (1) direct killing of tumor cells by inducing caspase-3/7 activation, (2) growth inhibition of tumor cell lines Rabbit polyclonal to AGBL5 through p21-mediated… Continue reading Supplementary Components5737159. antibody continues to be examined in preclinical tumor versions